Ryman Healthcare: How a Retirement-Village Champion Met Its Debt Reckoning

Ryman Healthcare is a case study in how a business that looks like a compounding machine on an accounting basis can run short of actual cash. This article explains how the retirement-village model works, why Ryman’s version was more generous to residents and more demanding of capital than its rivals’, how debt built up, what the 2023 and 2025 equity raisings fixed, what the FY2026 results show, and what the proposed reform of village law means for the company. It is part of the New Zealand Company Stories hub.

How did Ryman Healthcare begin?

Ryman was founded in Christchurch in 1984 by Kevin Hickman, a former police detective, and John Ryder, an accountant. The name combines their surnames. Their idea was a village in which independent living and hospital-level care sat on one site.

The story usually told is that Hickman, investigating a fire at a rest home, was dismayed by the conditions and decided the test for any facility should be whether it was good enough for his own mother. That phrase became company doctrine. The first village opened in Christchurch, and the firm grew steadily through the South Island before moving north.

Ryman listed on the NZX in 1999. For the next two decades it was one of the market’s most reliable performers, increasing underlying profit year after year and raising no new equity. Villages were named after notable locals, from Sir Edmund Hillary in Auckland to Weary Dunlop and Bert Newton in Melbourne, where the first Australian village opened in 2014. By 2026 the company operated 47 integrated villages across New Zealand and Victoria, housing more than 15,500 residents and employing about 7,800 people.

How does the retirement-village model make money?

A village operator sells the right to live in a unit, not the unit itself. The resident pays a capital sum, the operator repays it on departure less a deferred management fee, then resells the right to the next resident at the prevailing price and keeps any gain.

The legal instrument is an occupation right agreement, or ORA. Because the operator retains ownership of the land and buildings, residents’ capital sums function as interest-free funding. Three income streams follow:

• Development margin: the difference between the cost of building a unit and the price of its first sale.
• Deferred management fee: a percentage of the entry price, accrued over the first few years of occupation and deducted from the repayment when the resident leaves.
• Resale gain: when the unit is relicensed, the operator captures the whole increase in its value.

Residents also pay a weekly fee for village services, and care centres earn daily fees, much of it government-funded. Weekly fees and care rarely make much profit; in New Zealand, aged-residential-care funding has lagged costs for years. The money is in turnover of units. The mechanics across the wider industry, including rivals’ terms, are covered in the article on Summerset, Arvida and the retirement-village sector.

What made Ryman’s version of the model different?

Ryman offered residents the most generous terms in the industry: a deferred management fee capped at 20% when competitors charged 25% to 30%, and a weekly fee fixed for life. It also built a full care centre in every village, which is costly.

These terms were a selling point and a matter of pride. They were also, in hindsight, a subsidy. A fixed weekly fee meant that as rates, insurance and wages rose, the gap between what residents paid and what services cost widened every year a resident stayed. A 20% fee meant Ryman collected a third less than a rival on the same unit. And care centres, with large fixed staffing requirements and regulated prices, absorbed capital that earned little.

The model worked as long as two things held: house prices kept rising, so that resale gains and new sales prices climbed, and new units sold quickly, so that residents’ capital repaid construction debt. Ryman built on its own account, with in-house design and construction teams, on large sites that took years to complete. That raised quality and control but meant heavy spending well before the first resident moved in.

How did Ryman end up with too much debt?

Ryman funded an ambitious building programme in two countries with borrowings, expecting sales of new units to repay them. When the housing market turned in 2022 and interest rates rose, sales slowed, unsold stock accumulated and debt kept climbing.

Older buyers generally sell a house to fund entry to a village. When the New Zealand housing market fell sharply from late 2021, prospective residents either could not sell or would not accept the price. Settlements slowed while construction, much of it on large multi-storey buildings that cannot be paused halfway, continued. Net debt climbed to roughly NZ$3 billion.

Part of that debt was long-dated notes placed with American institutions, which carried covenants and became expensive to hold as conditions changed. In February 2023 Ryman raised NZ$902 million of equity, largely to repay those notes, and suspended its dividend. It was the company’s first capital raising since listing, and it was presented as a reset. It proved to be only the first half of one.

Through 2024 the chief executive, Richard Umbers, departed, the chairman Dean Hamilton stepped in as executive chair, and a review of the accounts produced restatements and write-downs. Naomi James, formerly of the fuel importer Refining NZ, was appointed chief executive later that year.

What happened in the 2025 capital raising?

In February 2025 Ryman raised NZ$1 billion of new equity at a discount of about 29% to its last share price, cutting net debt by more than a third. Ms James described the debt level before the raising, about NZ$2.6 billion, as uncomfortably high.

The offer comprised a placement to institutions of about NZ$313 million and a pro-rata offer to existing shareholders of about NZ$688 million. Coming two years after the first raising, at a far lower price, it was painful for long-term holders, who had been asked for NZ$1.9 billion in total. The discount reflected how little bargaining power the company had left.

The results for the year to March 2025 showed the damage and the repair together. Ryman reported a net loss of NZ$436.8 million after accounting changes, asset write-downs and higher interest costs. Net debt, however, fell by NZ$840 million to NZ$1.67 billion and gearing dropped to 28.1%. In November 2025 the company refinanced NZ$2.0 billion of bank facilities, and on 1 October 2025 it added a listing on the ASX, where investors are more familiar with the sector.

How has Ryman changed its pricing and fees?

From October 2024 Ryman lifted its standard deferred management fee from 20% to 30%, with a 25% option at a higher entry price, and gave new residents a choice between a weekly fee fixed for life and a lower fee that rises with inflation.

This was the abandonment of the terms that had defined the brand. Mr Hamilton explained it plainly at the time: people are living longer, residents are staying longer and costs have risen. The change applies only to new contracts; existing residents keep the terms they signed.

The effect on the economics of each unit is large. The average fee on new contracts rose from 20.7% to 28.8% within a year. On a NZ$900,000 apartment, that difference is worth more than NZ$70,000 to the operator each time the unit turns over. The risk was that buyers would walk away. Sales did soften at first, but by the March 2026 quarter the company reported that net sales applications were exceeding turnover for the first time since the change, and that the 30% option was widely accepted. Total ORA sales in FY2026 were 1,410, at the top of guidance.

What do the latest results show?

For the year to 31 March 2026, Ryman reported free cash flow of NZ$188 million, its first positive result in over a decade, operating revenue of NZ$849 million, up 10%, and operating earnings before interest, tax, depreciation and fair-value movements of NZ$88 million, up 94%.

Gearing ended the year at 27.8%, which the company describes as the lowest in the listed sector. About NZ$150 million of cash was released from completed developments as unsold stock was cleared, and land sales brought in NZ$72 million. Annualised cost savings ran ahead of the original target after three senior executive roles, including the Australian chief executive position, and many head-office jobs were removed. Two care centres were closed, with the company citing sector-wide underfunding.

Building has been cut to a fraction of its former pace. Ryman completed 330 units and beds in FY2026, against a record 950 the year before, and expects 157 to 168 in FY2027 with capital expenditure of NZ$150 million to NZ$180 million. In FY2025 it spent NZ$535 million. The business is still loss-making on its preferred pre-tax measure, at minus 7.2 cents a share against minus 54.1 cents a year earlier, and the board has outlined a pathway to resume dividends in FY2028.

Who owns and governs Ryman Healthcare?

Ryman is a widely held public company listed on the NZX and, since October 2025, the ASX. After two deeply discounted raisings its register is dominated by institutional investors, though tens of thousands of New Zealand retail investors and KiwiSaver members remain shareholders.

The founders’ families and the Hickman-linked holdings were diluted long ago, and no shareholder controls the company. Governance changed substantially during the crisis. Dean Hamilton, a former investment banker and Silver Fern Farms chief executive, became chair and for a period executive chair; Ms James took over as chief executive in late 2024; and much of the senior team and board turned over.

The episode has been bruising for the local market, described in the NZX story, because Ryman was among its most widely owned stocks. Like Fletcher Building, it became an example of a blue-chip that required repeated recapitalisation, and the managers profiled in the KiwiSaver story had to decide twice whether to put in more of their members’ money.

Who competes with Ryman Healthcare?

Ryman’s main competitors are Summerset, the fastest-growing listed operator; Metlifecare, owned by the Swedish private-equity firm EQT; Arvida, bought by the American infrastructure investor Stonepeak in 2024; Oceania Healthcare; and Bupa, alongside many charitable and family-owned operators.

The six largest operators have been estimated to control about 60% of the country’s village units. Summerset has taken Ryman’s old mantle as the sector’s growth stock, building more homes and keeping a lower-cost model of broad-acre villas, though it too has slowed its build rate and set a debt target. Private owners have an advantage in a downturn: they do not report quarterly and can hold stock until markets recover.

In Victoria, Ryman competes with Australian operators in a market where villages are less common and where its integrated care model is distinctive. It has about ten villages in Victoria, and Australia has at times been the more profitable half of the business.

What are the main risks facing Ryman?

The risks are a prolonged weak housing market, tighter regulation of village contracts, underfunded aged care, construction-cost inflation and the possibility that higher fees deter buyers once the current backlog of demand clears.

Housing remains the hinge. New Zealand house prices have been flat to weak since 2022, and village sales follow them with a lag. Regulation is the newer concern. The government’s review of the Retirement Villages Act produced proposals for mandatory repayment deadlines; the detail is covered in the sector article, but for Ryman the effect is to put a clock on a liability that previously had none.

Care is the structural drag. Ryman has about 4,700 aged-care beds at roughly 96% occupancy in mature centres, yet it is targeting earnings of only NZ$20,000 to NZ$25,000 a bed. A ministerial advisory group on aged-care funding has been formed, but there is no certainty of a better deal. The state is a hard bargainer across health, as the Pharmac story shows for medicines, and unlike Fisher & Paykel Healthcare, Ryman cannot look to export markets for better prices. Banks, including the Australian-owned lenders described in the Big Four banks story, will watch the covenant headroom closely.

What can founders and CFOs learn from Ryman Healthcare?

The lesson is that growth funded by debt and measured by non-cash profit can conceal a deteriorating business for years. The warning signs at Ryman were public; what was missing was a board willing to act on them while equity was still expensive.

1. Underlying profit is not cash. Any measure that includes revaluations or unrealised gains needs a cash reconciliation beside it in every board paper.
2. Generosity must be costed over a lifetime. A fixed-for-life price is a long-dated liability linked to inflation. It should be priced like one.
3. Match build rate to sales rate. Development that runs ahead of settlements converts a self-funding model into a leveraged property developer.
4. Raise equity once, and enough. The 2023 raising repaired one class of debt but left gearing too high. The second raising cost shareholders far more.
5. Reprice early. The move to a 30% fee was accepted by the market within about 18 months. Making it five years earlier would have funded much of the growth.

What happens next for Ryman Healthcare?

The next two years are about proving that the company can generate cash from its existing villages without the lift of new development, and about returning to dividends in FY2028 as the board has signalled, subject to performance.

Management has set targets to FY2029 of NZ$150 million of sustainable cash-flow improvement, of which NZ$47 million had been delivered by March 2026, and NZ$500 million of cash released from the balance sheet, of which NZ$169 million had been achieved. The land-sale target has been raised to about NZ$250 million, with NZ$147 million settled or contracted.

The strategic question is what Ryman becomes once the repair is done. It could resume building at a moderate pace, funded from cash flow; it could separate or partner its care operations; or, with a market value far below its earlier peak and private capital circling the sector, it could attract a bid, as Arvida did. For now the company is doing something it has not done since listing: living within its means.

Frequently Asked Questions